[Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].

The number of elderly patients with colorectal cancer is increasing in Japan. They have the opportunity to receive chemotherapy similar to non-elderly patients because of the development of new drug agents and improvement of supportive therapy. We analyzed retrospectively 184 patients (32 aged >or= 70, 75 or= 3 adverse events. The FOLFOX4 regimen maintains its efficacy/safety ratio in elderly patients with good performance status with colorectal cancer in Japan.